Feasibility of Using the Livongo-Insulia Study App for Patients With Type 2 Diabetes [Pilot Study]
Stopped early · Not applicable
Conditions studied: Type 2 Diabetes Treated With Insulin
In brief
The Livongo-Insulia Study App Pilot Study (LISA Pilot) is a 3-month, prospective, interventional study. The purpose of this pilot study is to evaluate the feasibility of using the Livongo-Insulia Study App for individuals with type 2 diabetes using basal insulin. This will be assessed by measuring the impact of the Livongo-Insulia Study App on glycemic control for these individuals.
Key facts
- Study ID
- NCT03980236
- Run by
- Livongo Health
- People needed
- 21
- Starts
- 2019-05-06
- Expected to finish
- 2020-05-31
- Last updated by the study team
- 2021-02-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age ≥ 18 years
- Lives in the U.S.
- Able to speak, read and write in English
- Diagnosed with type 2 diabetes
- Currently treated with long-acting basal insulin analog (Lantus, Levemir, Toujeo, Basaglar, Tresiba U-100) and taking 1 injection per day
- Takes a daily dose ≤ 0.75 units/kg
- Estimated A1c ≥ 8% (based on existing Livongo data)
- Has been enrolled in Livongo for at least 12 weeks
- Uses an iPhone compatible with Insulia's compatibility matrix (iPhone 5 or higher; iOS 8 or newer)
- Willing to complete study questionnaires
- Willing to complete at-home A1c kits
- Willing to check before breakfast blood glucose at least once per day
You may not qualify if…
- Diagnosis of type 1 diabetes
- Currently using a long-acting basal insulin analog that is not supported by Insulia
- Currently using rapid-acting, short-acting, or intermediate-acting or premixed insulins
- Currently pregnant or planning pregnancy
Where it is running
- Livongo — Mountain View, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.